| Title | PharmAbcine receives the ‘Best Poster Award’ for its additional nonclinical data presentation of PMC-309 at KSMO 2021
|
| Category | Press Release |
PharmAbcine receives the ‘Best Poster Award’ for its additional nonclinical data presentation of PMC-309 at KSMO 2021
PharmAbcine received the ‘Best Poster Award’ for its additional nonclinical data presentation of PMC-309, the company’s first immuno-oncology candidate, at KSMO (Korean Society of Medical Oncology) 2021 which took place over September 2-3, 2021. The Company also received the same award in the last year’s event.
This annual award is given to the companies that demonstrated excellent quality and novelty in their poster presentation. PharmAbcine became one of the few recipients for this award out of 275 companies that participated in this event.
PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody currently in development for the treatment of various tumor types. VISTA plays a pivotal role in maintaining the immunosuppressive environment around the tumor cells and is expressed primarily on MDSC (Myeloid-Derived Suppressor Cells).
The presentation at KSMO 2021 showed that PMC-309 with its VISTA-blocking mechanism:
- binds to immunosuppressing MDSCs unlike anti-PD-1 molecules which directly target T cells
- decreases the number of Treg (regulatory T cells), another key immunosuppressing cell, and increases T cell activation dose-dependently
- decreases the number of MDSCs and increased the number of T cells in the tumor microenvironment in in vivo study
- shows better anti-tumor effects when used in combo with an anti-PD-1 antibody
The data indicates that PMC-309 can be an excellent therapeutic drug because it has a unique mode of action can treat patients who do not respond to the existing drugs, inhibits immunosuppressive MDSCs and Tregs which lead to increased immune responses, and provides a strong scientific rationale for a combo therapy with its encouraging in vivo data.
■ Please check the attached files for more details. (Both full version and summarized version of e-poster available)
PharmAbcine receives the ‘Best Poster Award’ for its additional nonclinical data presentation of PMC-309 at KSMO 2021
PharmAbcine received the ‘Best Poster Award’ for its additional nonclinical data presentation of PMC-309, the company’s first immuno-oncology candidate, at KSMO (Korean Society of Medical Oncology) 2021 which took place over September 2-3, 2021. The Company also received the same award in the last year’s event.
This annual award is given to the companies that demonstrated excellent quality and novelty in their poster presentation. PharmAbcine became one of the few recipients for this award out of 275 companies that participated in this event.
PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody currently in development for the treatment of various tumor types. VISTA plays a pivotal role in maintaining the immunosuppressive environment around the tumor cells and is expressed primarily on MDSC (Myeloid-Derived Suppressor Cells).
The presentation at KSMO 2021 showed that PMC-309 with its VISTA-blocking mechanism:
- binds to immunosuppressing MDSCs unlike anti-PD-1 molecules which directly target T cells
- decreases the number of Treg (regulatory T cells), another key immunosuppressing cell, and increases T cell activation dose-dependently
- decreases the number of MDSCs and increased the number of T cells in the tumor microenvironment in in vivo study
- shows better anti-tumor effects when used in combo with an anti-PD-1 antibody
The data indicates that PMC-309 can be an excellent therapeutic drug because it has a unique mode of action can treat patients who do not respond to the existing drugs, inhibits immunosuppressive MDSCs and Tregs which lead to increased immune responses, and provides a strong scientific rationale for a combo therapy with its encouraging in vivo data.
■ Please check the attached files for more details. (Both full version and summarized version of e-poster available)